Advertisement
Advertisement

REPL

REPL logo

Replimune Group, Inc.

7.75
USD
Sponsored
+0.82
+11.79%
Feb 06, 16:00 UTC -5
Closed
exchange

After-Market

7.72

-0.03
-0.35%

REPL Earnings Reports

Positive Surprise Ratio

REPL beat 15 of 30 last estimates.

50%

Next Report

Next Week
Date of Next Report
Feb 10, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/
-$0.90
Implied change from Q2 26 (Revenue/ EPS)
--
/
--
Implied change from Q3 25 (Revenue/ EPS)
--
/
+13.92%

Replimune Group, Inc. earnings per share and revenue

On Nov 06, 2025, REPL reported earnings of -0.90 USD per share (EPS) for Q2 26, missing the estimate of -0.80 USD, resulting in a -12.32% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -0.93% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 10 analysts forecast an EPS of -0.90 USD, with revenue projected to reach -- USD, implying an increase of 0.00% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
logo
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
logo
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
logo
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
logo
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
logo
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
logo
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
logo
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
logo
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
logo
Adaptive Biotechnologies Corporation Common Stock
Report Date
Feb 05, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.09
Surprise
+51.33%
FAQ
For Q2 2026, Replimune Group, Inc. reported EPS of -$0.90, missing estimates by -12.32%, and revenue of $0.00, 0% as expectations.
The stock price moved down -0.93%, changed from $8.58 before the earnings release to $8.50 the day after.
The next earning report is scheduled for Feb 10, 2026.
Based on 10 analysts, Replimune Group, Inc. is expected to report EPS of -$0.90 and revenue of -- for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement